How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?

This is a challenging question and I'm not sure there's clear data to support a practice one way or another. Anecdotally, I have noticed that when using Luspatercept, it seems to improve hemoglobin reliably and therefore lead to less transfusions, but I have not observed a consistent concordant impr...